Insmed Incorporated (NASDAQ:INSM) Given Average Rating of “Buy” by Analysts

Insmed Incorporated (NASDAQ:INSM) has been given an average rating of “Buy” by the sixteen analysts that are currently covering the stock, MarketBeat Ratings reports. Sixteen analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $83.67.

A number of equities analysts have commented on INSM shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a research note on Monday, September 9th. Truist Financial reaffirmed a “buy” rating and issued a $105.00 price target (up from $100.00) on shares of Insmed in a research note on Friday, November 1st. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price target on shares of Insmed in a research note on Friday, November 1st. Bank of America lifted their price target on Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. Finally, JPMorgan Chase & Co. lifted their price target on Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a research note on Friday, November 22nd.

Institutional Investors Weigh In On Insmed

Several hedge funds have recently added to or reduced their stakes in INSM. V Square Quantitative Management LLC bought a new stake in Insmed in the third quarter worth $30,000. GAMMA Investing LLC boosted its holdings in Insmed by 71.3% in the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 224 shares in the last quarter. First Horizon Advisors Inc. boosted its holdings in Insmed by 83.4% in the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 287 shares in the last quarter. Exchange Traded Concepts LLC boosted its holdings in Insmed by 522.5% in the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 627 shares in the last quarter. Finally, CWM LLC boosted its holdings in Insmed by 11.0% in the second quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 155 shares in the last quarter.

Insmed Stock Performance

NASDAQ:INSM opened at $73.85 on Friday. The business has a 50 day moving average of $72.44 and a 200 day moving average of $71.56. The company has a market capitalization of $13.21 billion, a price-to-earnings ratio of -13.31 and a beta of 1.10. Insmed has a 1-year low of $21.92 and a 1-year high of $80.53. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The company had revenue of $93.40 million during the quarter, compared to the consensus estimate of $93.36 million. Insmed’s revenue was up 18.1% compared to the same quarter last year. During the same period last year, the firm earned ($1.10) EPS. On average, sell-side analysts predict that Insmed will post -5.44 earnings per share for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.